AbbVie (NYSE:ABBV) Stock Price Up 1.9% – What’s Next?

AbbVie Inc. (NYSE:ABBV)’s stock price was up 1.9% during trading on Monday . The company traded as high as $231.43 and last traded at $229.19. Approximately 5,461,304 shares changed hands during trading, a decline of 27% from the average daily volume of 7,430,835 shares. The stock had previously closed at $224.81.

Analysts Set New Price Targets

A number of brokerages have issued reports on ABBV. HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and increased their price objective for the company from $225.00 to $265.00 in a report on Wednesday, December 10th. Berenberg Bank set a $275.00 price target on shares of AbbVie in a report on Tuesday, January 20th. UBS Group dropped their price objective on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a report on Thursday, February 5th. JPMorgan Chase & Co. lifted their target price on AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a report on Monday, November 3rd. Finally, Wall Street Zen downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, AbbVie currently has a consensus rating of “Moderate Buy” and a consensus price target of $252.79.

AbbVie Stock Up 1.9%

The company has a 50 day simple moving average of $224.07 and a two-hundred day simple moving average of $222.45. The company has a market capitalization of $405.07 billion, a P/E ratio of 97.11, a PEG ratio of 0.78 and a beta of 0.35.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.65 by $0.06. The business had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The company’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same period last year, the company earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, research analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.0%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s payout ratio is presently 293.22%.

Institutional Investors Weigh In On AbbVie

Several institutional investors have recently made changes to their positions in ABBV. Chelsea Counsel Co. purchased a new stake in shares of AbbVie in the third quarter worth approximately $26,000. Litman Gregory Wealth Management LLC bought a new position in AbbVie in the 4th quarter valued at $28,000. Imprint Wealth LLC increased its stake in AbbVie by 56.3% in the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after purchasing an additional 45 shares during the period. Westend Capital Management LLC bought a new stake in shares of AbbVie during the fourth quarter worth $29,000. Finally, IFC & Insurance Marketing Inc. purchased a new stake in shares of AbbVie during the fourth quarter valued at $31,000. Institutional investors own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.